Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069484 | 1.00 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL17448116 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL17448117 | 0.85 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL25999644 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL1304195 | 0.81 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL28282222 | 0.81 | ACHE (0.46) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL17200854 | 0.80 | SSTR4 (0.35) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL27627765 | 0.77 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A | |
| SCHEMBL20695755 | 0.77 | ALDH1A1 (0.39) | — | |
| SCHEMBL21070072 | 0.76 | ITGB3 (0.43) | SLC6A2SLC6A4SLC6A3ADRB2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SLC6A2 4857/4885SLC6A4 4814/4885SLC6A3 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.